GILD vs RVMD stock comparison
Gilead Sciences vs. Revolution Medicines · data as of November 13, 2026
Gilead Sciences (GILD) has a market value of about $208.5B, Revolution Medicines (RVMD) about $37.3B. Over their latest twelve months Gilead Sciences had revenue of $31.0B and Revolution Medicines $198M.
On our five checks Gilead Sciences scores higher: 2.8 out of 5 (average) against 0.6 (weak).
By area, the stronger company is Gilead Sciences on value; Gilead Sciences on future growth; Gilead Sciences on track record; Gilead Sciences on financial health; Gilead Sciences on shareholder returns.
Gilead Sciences leads on 13 of the compared lines and Revolution Medicines on 2.
Side by side
| GILD | RVMD | |
|---|---|---|
| Size and price | ||
| Market cap | $208.5B | $37.3B |
| Share price | $168.08 | $172.29 |
| Score | ||
| Overall score (of 5) | 2.8 | 0.6 |
| Value | 1 | 0 |
| Future growth | 2 | 1 |
| Track record | 4 | 0 |
| Financial health | 3 | 2 |
| Shareholder returns | 4 | 0 |
| Valuation | ||
| P/E (TTM) | — | — |
| Forward P/E | 20.3 | — |
| Price / free cash flow | 15.1 | — |
| Price / sales | 6.7 | 188.6 |
| EV / EBITDA | 559.5 | — |
| PEG | — | — |
| DCF value vs. price | −35% | — |
| Business | ||
| Revenue | $31.0B | $198M |
| Net income | -$3.9B | -$1.9B |
| Free cash flow | $13.8B | -$1.4B |
| Net margin | -12.5% | -946.8% |
| Gross margin (5-yr avg.) | 77.6% | — |
| ROIC (5-yr avg.) | 12.2% | -36.5% |
| Growth | ||
| Revenue growth (1 yr) | 2.4% | — |
| Revenue growth (5 yrs, per year) | 3.6% | -100.0% |
| EPS growth (5 yrs, per year) | 132.4% | — |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | -$19.8B | — |
| Dividend yield | 1.95% | None |
| Shareholder yield | 2.9% | 0.0% |
| Analysts | ||
| Upside to average target | +4% | +59% |
| Consensus rating | Buy | Strong buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: GILD TTM to September 30, 2026, RVMD TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Gilead Sciences or Revolution Medicines?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Gilead Sciences scores 2.8 out of 5 and Revolution Medicines 0.6; the table shows where each one is stronger.
Which grows faster, Gilead Sciences or Revolution Medicines?
Over five years Gilead Sciences grew revenue about 3.6% a year and Revolution Medicines about -100.0% a year.
Which pays a higher dividend?
Gilead Sciences yields 1.95% and Revolution Medicines nothing (no dividend).
Full Gilead Sciences analysis → Full Revolution Medicines analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.